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Background: In 1950, the association between cigarette smoking and 
lung cancer was ﬁrmly established. However, adenocarcinoma of the 
lung comprised only about 5% of lung cancers at the time and appeared 
unrelated to smoking. In the 1960s and 1970s, incidence of adenocarci-
noma increased sharply, and became strongly related to smoking. 
Methods: SEER data on 307,797 lung cancer patients diagnosed in the 
US between 1975 and 2003 were analyzed. The objective was to assess 
changes in age-standardized incidence rates (per 100,000 population) 
at diagnosis of the four major lung cancer histologies: adenocarcinoma, 
squamous cell carcinoma, small cell carcinoma and large cell carci-
noma. Incidence of each histologic subtype was measured during six 
time periods (1975-1979, 1980-1984, 1985-1989, 1990-1994, 1995-
1999, 2000-2003). Comparisons were drawn based upon gender, race, 
and age. Because SEER contains no data on cigarette smoking, other 
sources were utilized to correlate changing histology to time trends 
in smoking prevalence, the changing cigarette, and Tobacco Institute 
actions. 
Results: Among all patients, adenocarcinoma surpassed squamous car-
cinoma by 1980-1984 to become the most common histologic subtype. 
The incidence of adenocarcinoma rose 62% between 1975-1979 and 
1995-1999, but then fell 8% in 2000-2003. Squamous cell incidence 
peaked in 1980-1984 and dropped by 35% by 2000-2003. Adenocar-
cinoma surpassed squamous cell in 1985-1989 in men, while adeno-
carcinoma had already become the most common form of lung cancer 
in women by 1975-1979. Adenocarcinoma rose 38% in men from 
1975-1979 to 1995-1999, while it doubled in women during this inter-
val. Among whites, adenocarcinoma surpassed squamous carcinoma 
by 1980-1984, although this did not occur among blacks for another 
decade. Nonetheless, incidence rate of adenocarcinoma has consistently 
been signiﬁcantly higher among black males than in other subgroups, 
while incidence of adenocarcinoma has been nearly identical among 
white and black women. Adenocarcinoma was already most common 
among patients <50 yrs of age by 1975-1979, while adenocarcinoma 
rapidly increased and surpassed squamous carcinoma in all other age 
groups by 1990-1994. By 2000-2003, adenocarcinoma comprised 
47% of all lung cancers (42% in men; 52% in women; 59% in pts <50 
yrs). Currently, adenocarcinoma is the most common histology in both 
sexes, races, and in all age groups. 
Conclusions: The dramatic rise of adenocarcinoma of the lung is 
consistent with the hypothesis that changes in cigarette design and 
composition were the major factors that were responsible for this 
rise. This increase has been most striking among women and younger 
persons. Trends in adenocarcinoma correlate with the wide-scale adop-
tion by smokers of ﬁltered and low tar cigarettes, and with increasing 
nitrosamine levels in cigarettes. While ﬁltered cigarettes comprised 
only 1% of the market in 1950, their use rapidly increased to 64% in 
1964 and 95% in 1986. Today 98% of cigarettes made in the US are 
ﬁltered. Speciﬁcally, the use of ﬁlter vents in cigarette design likely 
played a substantial role in this rapid rise of adenocarcinoma of the 
lung. The use of ﬁlter vents reduces the resistance to draw allowing 
smokers to take bigger, deeper puffs thereby facilitating the delivery 
of smoke particles deep into the airways. These changes were intro-
duced by the Tobacco Industry in response to mounting evidence that 
cigarette smoking caused other forms of lung cancer. These actions by 
the Tobacco Industry contributed to the development of an epidemic of 
smoking-related adenocarcinoma of the lung.
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Background: This Phase III, randomized, open-label, multicenter, 
parallel-group study (INTEREST [IRESSA non-small-cell lung cancer 
(NSCLC) Trial Evaluating REsponse and Survival against Taxotere]), 
compared geﬁtinib with docetaxel in patients with locally advanced 
or metastatic NSCLC pretreated with platinum-based chemotherapy. 
This is the largest reported Phase III study comparing targeted therapy 
(geﬁtinib) with chemotherapy (docetaxel).
Methods: Patients (≥18 years, performance status [PS] 0-2) with lo-
cally advanced or metastatic NSCLC who had progressed or recurred 
following 1 or 2 prior chemotherapy regimens (at least 1 platinum-
based) were randomized to receive geﬁtinib (250 mg/day orally) or 
docetaxel (75 mg/m2 iv every 3 weeks). The primary objective was to 
compare overall survival between geﬁtinib and docetaxel using a co-
primary analysis in both the overall population (non-inferiority) and, as 
a protocol amendment following the emergence of biomarker data, in 
patients with high epidermal growth factor receptor (EGFR) gene copy 
number (measured by ﬂuorescence in situ hybridization) (superiority). 
Secondary endpoints were progression free survival, objective response 
rate (assessed by RECIST), patient-reported functionality and quality 
of life (measured using the Functional Assessment of Cancer Therapy-
Lung total score, trial outcome index and lung cancer subscale), and 
safety and tolerability (according to Common Toxicity Criteria version 
2.0). Exploratory endpoints including other biomarkers and quality of 
life endpoints were also assessed. A Cox proportional hazards model 
analysis adjusting only for randomized treatment was used to compare 
overall survival between the randomized treatments. 
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Results: 1466 patients from 149 centers in 24 countries were random-
ized to geﬁtinib (n=733) or docetaxel (n=733); 323 patients were of 
Asian racial origin. In the geﬁtinib and docetaxel treatment arms, 
respectively, 54% and 55% had adenocarcinoma, 36% and 33% were 
female, and 20% and 21% were never-smokers. 30%, 58%, 12% and 
25%, 63%, 12% had PS 0, 1, 2 in the geﬁtinib and docetaxel treatment 
arms, respectively and 15% and 17%, respectively, had undergone 2 
prior chemotherapy regimens. 453 patients provided a tumour sample 
giving at least one evaluable biomarker. Full results will be presented at 
the conference.
Conclusions: In this Phase III study comparing geﬁtinib with docetaxel 
in patients with locally advanced or metastatic NSCLC pretreated with 
platinum-based chemotherapy, the treatment groups were well balanced 
in terms of patient demographics and baseline characteristics. Full 
results will be presented at the conference.
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Background: Platinum-based chemotherapy is the standard of care for 
ﬁrst-line treatment of locally advanced and metastatic NSCLC. Gem-
citabine-cisplatin (GC) is a widely used doublet in this setting. In phase 
II studies, efﬁcacy results of pemetrexed-platinum doublets compare 
favorably with other active platinum-doublets. The combination of 
pemetrexed plus cisplatin (PC) has the potential to have similar efﬁcacy 
with more tolerability and more convenient administration. 
Methods: Patients with previously untreated stage IIIB or IV NSCLC 
and an ECOG PS of 0-1 were randomized to receive PC (P 500 mg/m2 
d1; C 75 mg/m2 d1) or GC (G 1250 mg/m2 d1,8; C 75 mg/m2 d1), every 
three weeks, up to 6 cycles. Both arms received folic acid, vitamin B12 
and dexamethasone. Randomization factors included stage, PS, gender, 
and history of brain metastases. The primary endpoint of this non-infe-
riority study was overall survival. Using the Cox proportional hazards 
model and a two-tailed 95% CI for the hazard ratio (HR), rejection of 
H0 occurs when the upper-bound of the HR CI is <1.17647, with an 
80% probability of rejecting H0 based on 1190 events. 
Results: From July 2004 to December 2005, 1725 patients were ran-
domized from 177 sites in 26 countries to PC (n=862) or GC (n=863). 
Both known prognostic factors and patient and disease characteristics 
were well-balanced between arms: median age 61 years, 70% male, 
64% PS 1, 76% stage IV NSCLC, 78% Caucasian, and 15% never 
smokers. Overall survival for patients randomized to PC was non-in-
ferior to GC (10.3 vs 10.3 mo [HR 0.94, 95%CI 0.84-1.05]), with the 
95% CI for HR included in the 1.176 non-inferiority margin. Progres-
sion free survival and response rates showed similarly robust non-
inferiority for PC vs GC (4.8 vs 5.1 mo [HR 1.04, 95%CI 0.94-1.15] 
and 31% vs 28%). Survival rates at 12 and 24 months were 43.5% 
vs 41.9% and 18.9% vs 14.0%, respectively. Hematologic grade 3/4 
drug-related toxicities were signiﬁcantly (p ≤ 0.001) lower for PC; 
neutropenia (15% vs 27%), anemia (6% vs 10%), and thrombocytope-
nia (4% vs 13%). Febrile neutropenia (grade 3/4, 1% vs 4%, p=0.002) 
and alopecia (12% vs 21%, p<0.001) were signiﬁcantly less for PC. 
Less grade 3/4 nausea (7% vs 4%, p=0.004) and anorexia (2% vs 1%, 
p=0.009) were observed for GC. In a pre-speciﬁed analysis of survival 
by histologic groups, PC had signiﬁcantly better survival than GC in 
adenocarcinoma (n=847, 12.6 vs 10.9 mo [HR 0.84, CI 0.71-0.98]) and 
in large cell histology (n=153, 10.4 vs 6.7 mo [HR 0.68, CI 0.48-0.97]). 
In contrast, there was a non signiﬁcant trend toward better survival with 
GC in squamous cell histology (n=473, 9.4 vs 10.8 mo [HR 1.22, CI 
0.99-1.50]). 
Conclusion: For ﬁrst-line treatment of advanced NSCLC, PC provides 
similar efﬁcacy with better tolerability and more convenient admin-
istration than GC. In addition, this is the ﬁrst NSCLC trial to report 
survival differences between platinum doublets according to histology, 
which may impact future treatment decisions.
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small cell lung cancer (SCLC)
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Background: Small cell lung cancer (SCLC) is a highly angiogenic tu-
mour. We hypothesized that thalidomide, an anti-angiogenic agent with 
tumour vasculature stabilizing, anti-cachexic and immuno-modulatory 
properties, when combined with chemotherapy and as maintenance 
treatment would improve survival in patients with poor prognosis 
SCLC. We previously demonstrated in a phase II study that low dose 
thalidomide when combined with chemotherapy and as maintenance 
agent was well tolerated without signiﬁcant toxicity (Lee, ASCO 
2002). Moreover, a randomized trial of 92 patients with extended-dis-
ease SCLC, who responded to chemotherapy, demonstrated a 3 month 
increase in survival in patients receiving thalidomide compared to 
placebo (Pujol ASCO 2006). Here, we present the preliminary results 
of a large randomised phase III trial of thalidomide in SCLC. 
Methods: Chemo-naive patients were entered into a double-blind 
placebo-controlled trial. Eligibility criteria included histologically or 
cytologically conﬁrmed SCLC, extensive or limited disease, age over 
18 years, ECOG performance status 0-3 and life expectancy of greater 
than 8 weeks. They were enrolled from 79 UK centres. All patients 
received up to 6 courses, every 3 weeks of Etoposide (120 mg/m2 IV on 
days 1 & 2, and 100mg bd given orally on day 3 or, given on day 2, in-
stead of IV, if required) and Carboplatin (AUC 5 or 6 given on day 1). 
Patients were randomized to receive placebo or thalidomide capsules, 
taken orally from starting chemotherapy, daily, for up to 2 years. The 
dose began at 100mg/day at the start of chemotherapy. If the patient 
was able to tolerate this dose, it was increased to 150mg/day at the end 
of chemotherapy for one month, then to 200mg/day for the rest of the 
trial. Thoracic radiotherapy and prophylactic cranial irradiation were 
offered to patients with initially limited disease who had a complete 
or partial response. Strict guidelines were given regarding contrace-
